The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
Détails
ID Serval
serval:BIB_C0EF3DC2B414
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
Périodique
Alimentary Pharmacology & Therapeutics
ISSN
1365-2036[electronic]
Statut éditorial
Publié
Date de publication
2010
Volume
31
Numéro
1
Pages
92-101
Langue
anglais
Résumé
BACKGROUND: Adalimumab (ADA) and certolizumab pegol (CZP) have demonstrated efficacy in Crohn's disease (CD) patients previously treated with infliximab (IFX). AIM: To assess the efficacy and tolerability of a third anti-TNF in CD after failure of and/or intolerance to two different anti-TNF antibodies. METHODS: Crohn's disease patients who received ADA or CZP after loss of response and/or intolerance to two anti-TNF agent were included in this retrospective study. Data were collected using a standardized questionnaire. Clinical response, duration, safety and reasons for discontinuation were assessed. RESULTS: Sixty-seven patients treated with CZP (n = 40) or ADA (n = 27) were included. A clinical response was observed in 41 (61%) at week 6 and 34 patients (51%) at week 20. The probability of remaining under treatment at 3 months, 6 months and 9 months was 68%, 60% and 45%, respectively. At the end of follow-up, the third anti-TNF had been stopped in 36 patients for intolerance (n = 13), or failure (n = 23). Two deaths were observed. CONCLUSIONS: The treatment with a third anti-TNF (CZP or ADA) agent of CD patients, who have experienced loss of response and/or intolerance to two anti-TNF antibodies, has favourable short-term and long-term efficacy. It is an option to be considered in patients with no other therapeutic options.
Mots-clé
Antitumor Necrosis Factor, Inflammatory-Bowel-Disease, Certolizumab Pegol CDP870, Factor-Alpha, Maintenance Therapy, Open-Label, Clinical-Response, Randomized-Trial, Sture Registry, Lost Response
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/12/2009 17:41
Dernière modification de la notice
20/08/2019 16:35